We do not manufacture packaging that merely looks professional. We produce analytical data that a third party can reproduce.
In 2019, our founder was still buying for a contract research organization. A bulk peptide order was retested in the lab and came back nearly four percentage points below the purity stated on the seller's report — the report was old, the batch was new.
After that return, we decided to do it ourselves: every batch carries its own number, every report maps to a specific test date and instrument trace, and customers can check the number themselves.
Vireo Peptides was founded on that basis. We put our budget into third-party testing, batch management and packaging stability rather than oversized marketing claims.
If we cannot meet any one of them, the batch does not go on sale.
No new product goes live until both HPLC and LC-MS are complete. We do not take pre-orders before the report exists, and historical reports stay on file permanently.
Samples from different batches are numbered and stored separately, and each order is bound to its batch number at dispatch. We never mix old and new batches or reuse a report.
We supply research institutions and individuals with suitable laboratory facilities only. Any inquiry involving human use is declined, with an explanation.
Small, ready-to-ship quantities for molecular biology, pharmacology and cell biology groups, with pack sizes that fit project budgets.
Batch-to-batch consistency plus complete COA records for method validation and audit trails.
Low minimum order sizes, technical advice and help confirming dissolution and storage protocols, so early experiments cost less to iterate.
No order required. The COA page publishes HPLC purity and LC-MS results for every batch on sale, so you can verify the data before you decide.